University of Iowa Health Care

Ophthalmology and Visual Sciences

EyeRounds.org

Thyroid Eye Disease: An Introductory Tutorial and Overview of Disease

References

  1. Douglas RS, Gupta S. The pathophysiology of thyroid eye disease: implications for immunotherapy. Curr Opin Ophthalmol 2011;22(5):385-390. [PMID 21730841]
  2. Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, Gorman CA. Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996;121(3):284-290. [PMID 8597271]
  3. Krassas GE, Wiersinga W. Smoking and autoimmune thyroid disease: the plot thickens. Eur J Endocrinol 2006;154(6):777-780. [PMID 16728534]
  4. Kazim M, Goldberg RA, Smith TJ. Insights into the pathogenesis of thyroid-associated orbitopathy: evolving rationale for therapy. Arch Ophthalmol 2002;120(3):380-386. [PMID 11879144]
  5. Smith TJ, Koumas L, Gagnon A, Bell A, Sempowski GD, Phipps RP, Sorisky A. Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2002;87(1):385-392. [PMID 11788681]
  6. Tsui S, Naik V, Hoa N, Hwang CJ, Afifiyan NF, Sinha Hikim A, Gianoukakis AG, Douglas RS, Smith TJ. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease. J Immunol 2008;181(6):4397-4405. [PMID 18768899]
  7. Naik V, Khadavi N, Naik MN, Hwang C, Goldberg RA, Tsirbas A, Smith TJ, Douglas RS. Biologic therapeutics in thyroid-associated ophthalmopathy: translating disease mechanism into therapy. Thyroid 2008;18(9):967-971. [PMID 18713027]
  8. Ponto KA, Zang S, Kahaly GJ. The tale of radioiodine and Graves' orbitopathy. Thyroid 2010;20(7):785-793. [PMID 20578895]
  9. Holds JB, Buchanan AG. Graves orbitopathy. Focal Points: Clinical Modules for Ophthalmologists. Module 11. San Francisco: American Academy of Ophthalmology; 2010.
  10. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998;338(2):73-78. [PMID 9420337]
  11. Talke LM, Murchison AP. Globe Subluxation: Review and Management. Review of Ophthalmology 2007;14 (https://www.reviewofophthalmology.com/article/globe-subluxation-review-and-management)
  12. Dolman PJ, Cahill K, Czyz CN, Douglas RS, Elner VM, Feldon S, Kazim M, Lucarelli M, Sivak-Collcott J, Stacey AW, Strianese D, Uddin J. Reliability of estimating ductions in thyroid eye disease: an International Thyroid Eye Disease Society multicenter study. Ophthalmology 2012;119(2):382-389. [PMID 21959369]
  13. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 1997;47(1):9-14. [PMID 9302365]
  14. Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol (Oxf) 2000;52(3):267-271. [PMID 10718823]
  15. Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Curro N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marino M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM, European Group on Graves O. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008;158(3):273-285. [PMID 18299459]
  16. Stan MN, Garrity JA, Bahn RS. The evaluation and treatment of graves ophthalmopathy. Med Clin North Am 2012;96(2):311-328. [PMID 22443978]
  17. Cawood T, Moriarty P, O'Shea D. Recent developments in thyroid eye disease. BMJ 2004;329(7462):385-390. [PMID 15310608]
  18. Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, Altea MA, Nardi M, Pitz S, Boboridis K, Sivelli P, von Arx G, Mourits MP, Baldeschi L, Bencivelli W, Wiersinga W, European Group on Graves O. Selenium and the course of mild Graves' orbitopathy. N Engl J Med 2011;364(20):1920-1931. [PMID 21591944]
  19. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 2000;21(2):168-199. [PMID 10782363]
  20. Prummel MF, et al. Amelioration of eye changes of Graves' ophthalmolopathy by achieving euthyroidism. Acta Endocrinology (Copenhagen) 1989;121 (suppl 2):185-189
  21. Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, editors. Williams Textbook of Endocrinology. 11th ed. Philadelphia: Elsevier/Saunders, 2008.
  22. Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN, American Thyroid Association, American Association of Clinical Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 2011;21(6):593-646. [PMID 21510801]
  23. Stan MN, Durski JM, Brito JP, Bhagra S, Thapa P, Bahn RS. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment. Thyroid 2013;23(5):620-625. [PMID 23205939]
  24. Eckstein A, Quadbeck B, Mueller G, Rettenmeier AW, Hoermann R, Mann K, Steuhl P, Esser J. Impact of smoking on the response to treatment of thyroid associated ophthalmopathy. Br J Ophthalmol 2003;87(6):773-776. [PMID 12770979]
  25. Vannucchi G, Covelli D, Campi I, Origo D, Curro N, Cirello V, Dazzi D, Beck-Peccoz P, Salvi M. The therapeutic outcome to intravenous steroid therapy for active Graves' orbitopathy is influenced by the time of response but not polymorphisms of the glucocorticoid receptor. Eur J Endocrinol 2014;170(1):55-61. [PMID 24128430]
  26. Rajendram R, Bunce C, Lee RW, Morley AM. Orbital radiotherapy for adult thyroid eye disease. Cochrane Database Syst Rev 2012;10.1002/14651858.CD007114.pub2(7):CD007114. [PMID 22786503]
  27. Shams PN, Ma R, Pickles T, Rootman J, Dolman PJ. Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease. Am J Ophthalmol 2014;157(6):1299-1305. [PMID 24582992]
  28. Kazim M. Perspective--Part II: radiotherapy for Graves Orbitopathy: the Columbia University experience. Ophthal Plast Reconstr Surg 2002;18(3):173-174. [PMID 12021645]
  29. Wakelkamp IM, Tan H, Saeed P, Schlingemann RO, Verbraak FD, Blank LE, Prummel MF, Wiersinga WM. Orbital irradiation for Graves' ophthalmopathy: Is it safe? A long-term follow-up study. Ophthalmology 2004;111(8):1557-1562. [PMID 15288988]
  30. Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with Graves' orbitopathy. J Clin Endocrinol Metab 2015;100(2):432-441. [PMID 25343233]
  31. Rajendram R, Lee RW, Potts MJ, Rose GE, Jain R, Olver JM, Bremner F, Hurel S, Cook A, Gattamaneni R, Tomlinson M, Plowman N, Bunce C, Hollinghurst SP, Kingston L, Jackson S, Dick AD, Rumsey N, Morris OC, Dayan CM, Uddin JM. Protocol for the combined immunosuppression & radiotherapy in thyroid eye disease (CIRTED) trial: a multi-centre, double-masked, factorial randomised controlled trial. Trials 2008;9:6. [PMID 18237441]
  32. Silkiss RZ, Reier A, Coleman M, Lauer SA. Rituximab for thyroid eye disease. Ophthal Plast Reconstr Surg 2010;26(5):310-314. [PMID 20562667]
  33. Wakelkamp IM, Baldeschi L, Saeed P, Mourits MP, Prummel MF, Wiersinga WM. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial. Clin Endocrinol (Oxf) 2005;63(3):323-328. [PMID 16117821]
  34. Prummel MF, Mourits MP, Blank L, Berghout A, Koornneef L, Wiersinga WM. Randomized double-blind trial of prednisone versus radiotherapy in Graves' ophthalmopathy. Lancet 1993;342(8877):949-954. [PMID 8105213]
  35. Fayers T, Barker LE, Verity DH, Rose GE. Oscillopsia after lateral wall orbital decompression. Ophthalmology 2013;120(9):1920-1923. [PMID 23618229]
  36. Trokel S, Kazim M, Moore S. Orbital fat removal. Decompression for Graves orbitopathy. Ophthalmology 1993;100(5):674-682. [PMID 8493010]
  37. Tse DT. A simple maneuver to reposit a subluxed globe. Arch Ophthalmol 2000;118(3):410-411. [PMID 10721966]
  38. Chang EL, Bernardino CR, Rubin PA. Normalization of upper eyelid height and contour after bony decompression in thyroid-related ophthalmopathy: a digital image analysis. Arch Ophthalmol 2004;122(12):1882-1885. [PMID 15596598]
  39. Thomas SM, Cruz OA. Comparison of two different surgical techniques for the treatment of strabismus in dysthyroid ophthalmopathy. J AAPOS 2007;11(3):258-261. [PMID 17572340]
  40. Nerad JA. Oculoplastic Surgery: The Requisites in Ophthalmology. St. Louis, MO: Mosby, 2001.
  41. Morgenstern KE, Evanchan J, Foster JA, Cahill KV, Burns JA, Holck DE, Perry JD, Wulc AE. Botulinum toxin type a for dysthyroid upper eyelid retraction. Ophthal Plast Reconstr Surg 2004;20(3):181-185. [PMID 15167723]

Back

last updated: 11/18/2016
Share this page: